| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | N-acylethanolamine-hydrolyzing acid amidase, 351-, Acid ceramidase-like protein, N-acylsphingosine amidohydrolase-like, ASAH-like protein, N-acylethanolamine-hydrolyzing acid amidase subunit alpha, N-acylethanolamine-hydrolyzing acid amidase subunit beta, NAAA, ASAHL, PLT |
| Entrez GeneID | 27163 |
| WB Predicted band size | 40.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This NAAA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 331-359 amino acids from the C-terminal region of human NAAA. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与NAAA抗体相关的研究文献摘要，按研究领域分类整理：
### 1. **《Discovery of potent and selective NAAA inhibitors as potential analgesic agents》**
- **作者**: Piomelli D. et al.
- **摘要**: 研究报道了一种新型NAAA特异性抑制剂的开发，通过阻断NAAA水解棕榈酰乙醇酰胺(PEA)的活性，增强内源性大麻素的抗炎和镇痛作用。动物实验显示该抑制剂可显著缓解神经性疼痛模型中的痛觉敏感。
### 2. **《NAAA regulates microglial polarization via PPARα in neuroinflammation》**
- **作者**: Syed Y.Y. et al.
- **摘要**: 利用NAAA特异性抗体揭示了NAAA在中枢神经炎症中的作用机制，证明抑制NAAA可通过激活PPARα通路抑制小胶质细胞M1型极化，减轻小鼠多发性硬化模型的神经损伤。
### 3. **《Targeting NAAA in peripheral macrophages ameliorates osteoarthritis progression》**
- **作者**: Chen H. et al.
- **摘要**: 研究发现NAAA在骨关节炎滑膜巨噬细胞中高表达，使用单克隆抗体阻断NAAA活性可减少促炎因子释放，并通过LC-MS/MS验证其对PEA代谢的调控作用，显著延缓软骨退化进程。
---
### 研究领域覆盖：
- **药物开发**(特异性抑制剂设计)
- **神经科学**(疼痛与神经炎症调控)
- **骨关节疾病**(巨噬细胞介导的炎症机制)
如需具体DOI或发表年份可补充说明。
NAAA (N-acylethanolamine acid amidase) is a lysosomal enzyme that hydrolyzes bioactive N-acylethanolamines (NAEs), including palmitoylethanolamide (PEA), an endogenous lipid mediator with anti-inflammatory and analgesic properties. Discovered in the early 2000s, NAAA is primarily expressed in immune cells, macrophages, and tissues like the lungs, kidneys, and brain. Its enzymatic activity is pH-dependent, requiring an acidic environment for optimal function. Dysregulation of NAAA has been implicated in chronic inflammatory conditions (e.g., multiple sclerosis, colitis), neuropathic pain, and metabolic disorders, as impaired NAE degradation may exacerbate inflammation or disrupt lipid signaling pathways.
NAAA antibodies, developed for research and diagnostic purposes, enable the detection and quantification of NAAA protein levels in biological samples. These antibodies are critical tools for studying NAAA's tissue distribution, expression patterns under disease states, and interactions with inhibitors. Recent therapeutic strategies focus on developing NAAA-specific inhibitors to boost endogenous PEA levels, offering potential treatments for inflammatory diseases. However, challenges remain in ensuring antibody specificity due to structural similarities with other serine hydrolases. Ongoing research aims to refine antibody design and explore NAAA's role in cellular pathways, advancing both biomarker discovery and targeted therapies.
×
